checkAd

    +++ Und wieder 27 % Plus +++ - 500 Beiträge pro Seite

    eröffnet am 27.12.04 20:33:50 von
    neuester Beitrag 23.01.05 18:46:26 von
    Beiträge: 7
    ID: 939.064
    Aufrufe heute: 0
    Gesamt: 1.433
    Aktive User: 0

    ISIN: US74837Q1067 · WKN: 213757 · Symbol: QMDT
    0,0000
     
    USD
    -99,50 %
    -0,0002 USD
    Letzter Kurs 09.02.24 Nasdaq OTC

    Werte aus der Branche Gesundheitswesen

    WertpapierKursPerf. %
    1,2000+99.999,00
    0,8452+42,05
    3,1400+33,05
    3,3050+24,25
    1,7300+23,57
    WertpapierKursPerf. %
    1,0300-15,57
    1,6700-19,71
    1,0100-30,82
    17,100-50,29
    16,550-67,06

     Durchsuchen

    Begriffe und/oder Benutzer

     

    Top-Postings

     Ja Nein
      Avatar
      schrieb am 27.12.04 20:33:50
      Beitrag Nr. 1 ()
      Nach excellenten News am vergangenen Handelstag gehts heute erneut 27 % hoch - packen wir heute den Dollar (bin zu 0.53 cents rein :lick: )




      Quick-Med Technologies, Inc. Signs Research Agreement with Johnson & Johnson Wound Management



      GAINESVILLE, Fla.--(BUSINESS WIRE)--Dec. 23, 2004--Quick-Med Technologies, Inc. (OTCBB:QMDT) announced today that it has entered into a six-month research agreement with Johnson & Johnson :eek: Wound Management, a division of ETHICON INC., a Johnson & Johnson company, to investigate applications of their NIMBUS(TM) antimicrobial technology to advanced wound care products.

      "We are very pleased to be collaborating with Johnson & Johnson Wound Management," said Mr. David S. Lerner, President of Quick-Med Technologies. "This collaboration is another validation of the capabilities of our NIMBUS(TM) technology." added Mr. Lerner.

      The specific terms of the agreement were not disclosed.

      About Quick-Med Technologies, Inc.
      Quick-Med Technologies is a life sciences company focused on developing proprietary, broad-based technologies for consumer, industrial, and healthcare use, as well as for advanced military and civilian medical applications. The Company`s two core products under development are: (1) MultiStat(TM), a family of advanced compounds shown to be effective in broad-based skin therapy applications; and (2) NIMBUS(TM), a family of advanced polymers that can be used in a wide range of applications from advanced wound care to industrial and consumer preservatives. Quick-Med Technologies is listed under the symbol "QMDT" on the OTC Bulletin Board. For additional information, visit Quick-Med Technologies` website: http://www.quickmedtech.com or email: info@quickmedtech.com for further information.

      Certain statements in this press release constitute "forward-looking statements". Such forward-looking statements involve known and unknown risks, certainties and other factors, which may cause the actual results, performance of achievements of Quick-Med Technologies, Inc. (the "Company") to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. There is no assurance that the Company will complete any transactions, whether with Johnson & Johnson Wound Management or otherwise. The signing of an agreement with Johnson & Johnson Wound Management should not be construed by any means as an indication of the Company`s future financial performance or the future value of its common stock. Furthermore, the Company`s future operating results are dependent upon many factors, including whether the Company will ever successfully launch its potential technologies and/or products and the risk factors contained in its periodic and other filings, which are available for review at www.sec.gov. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events, or circumstances after the date of such statement.


      CONTACT: Quick-Med Technologies, Inc.
      David S. Lerner, 561-750-4202
      Email: dlerner@quickmedtech.com
      or
      Investor Relations, 403-203-4748
      Email: info@quickmedtech.com
      Website: www.quickmedtech.com

      SOURCE: Quick-Med Technologies, Inc.
      Avatar
      schrieb am 27.12.04 20:34:53
      Beitrag Nr. 2 ()
      Hier das Orderbuch :D

      MMID Bid Bid Size MMID Ask Ask Size
      QMDT Bullet Quote PulseChart
      SCHB 0.810 25 SCHB 0.870 25
      NITE 0.800 25 JPTC 0.900 25
      HILL 0.750 25 GNET 0.950 25
      GVRC 0.710 25 VNDM 1.000 25:D
      FRAN 0.610 25 JEFF 1.010 5
      TDCM 0.600 25 STCS 1.010 5
      JPTC 0.590 25 VERT 1.010 5
      VFIN 0.550 25 BAMM 1.010 5
      BAMM 0.540 25 HILL 1.010 5
      JEFF 0.300 50 TDCM 1.010 5
      SACM 0.300 50 NITE 1.010 5
      VERT 0.260 50 CRWN 1.020 5
      CRWN 0.250 50 HDSN 1.020 5
      VNDM 0.240 50 PERT 1.050 5
      PERT 0.080 50 GVRC 1.050 5
      HDSN 0.050 50 SACM 1.200 5
      STCS 0.010 50 VFIN 1.300 5
      GNET 0.000 0 FRAN 1.300 5
      Avatar
      schrieb am 27.12.04 21:14:45
      Beitrag Nr. 3 ()
      ASK 0.90 - die letzte Stunde wird nochmals gekauft :eek: :lick:
      Avatar
      schrieb am 27.12.04 21:31:30
      Beitrag Nr. 4 ()
      Völliger Schrott, darüberhinaus nichtmal in DE handelbar. Selbst in Amiland ist das Volumen dürftig...empfehl nächstes Mal bitte eine vernünftige Aktie, zur Ausnahme !
      Avatar
      schrieb am 27.12.04 21:40:00
      Beitrag Nr. 5 ()
      :laugh::laugh::laugh:

      Trading Spotlight

      Anzeige
      Rallye II. – Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…mehr zur Aktie »
      Avatar
      schrieb am 31.12.04 13:55:52
      Beitrag Nr. 6 ()
      Quick-Med Technologies, Inc. Annual Meeting of Stockholders Held December 13, 2004



      GAINESVILLE, Fla.--(BUSINESS WIRE)--Dec. 31, 2004--Quick-Med Technologies, Inc. (OTCBB: QMDT) held its Annual Meeting of Stockholders on December 13, 2004. At the Meeting, all of the resolutions proposed by management were approved.

      The Stockholders re-elected all seven current Board members: Michael R. Granito, David S. Lerner, Paul G. Cerjan, George E. Friel, Gerald M. Olderman, Gregory S. Schultz and Richard F. Caffrey.

      The Stockholders reappointed DaszkalBolton, LLP as the Company`s independent accountants until the next Annual Meeting of Stockholders.

      The Stockholders approved the proposal to adopt the Amended and Restated 2001 Equity Incentive Plan.

      The Stockholders approved amendments of the Company`s Articles of Incorporation and By-laws to increase the maximum number of directors from the current seven (7) to nine (9).

      The Stockholders approved a proposed amendment to the Company`s By-laws, such that the latest date for holding an Annual Meeting of Stockholders was extended to six (6) months following the Company`s fiscal year end and within fifteen (15) months after the last Annual Meeting.

      The Stockholders approved an amendment of the Company`s By-laws with respect to the use of written consent resolutions of a majority of stockholders in lieu of Stockholder Meetings.

      Two additional motions were approved at the Annual Meeting. The Stockholders approved all actions of the Company`s Directors since the last Annual Meeting, and the Stockholders accepted the Company`s electronic filling of its Annual Report on Form 10-KSB/A with the Securities and Exchange Commission in October 2004 as delivery of such Annual Report to the Stockholders.

      About Quick-Med Technologies, Inc.

      Quick-Med Technologies is a life sciences company focused on developing proprietary, broad-based technologies for consumer, industrial, and healthcare use, as well as for advanced military and civilian medical applications. The Company`s two core products under development are: (1) MultiStat(TM), a family of advanced compounds shown to be effective in broad-based skin therapy applications; and (2) NIMBUS(TM), a family of advanced polymers that can be used in a wide range of applications from advanced wound care to industrial and consumer preservatives. Quick-Med Technologies is listed under the symbol "QMDT" on the OTC Bulletin Board. For additional information, visit Quick-Med Technologies` website: http://www.quickmedtech.com or email: info@quickmedtech.com for further information.

      Certain statements in this press release constitute "forward-looking statements". Such forward-looking statements involve known and unknown risks, certainties and other factors, which may cause the actual results, performance of achievements of Quick-Med Technologies, Inc. (the "Company") to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. The Company`s future operating results are dependent upon many factors, including whether the Company will ever successfully launch its potential technologies and/or products and the risk factors contained in its periodic and other filings, which are available for review at www.sec.gov. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events, or circumstances after the date of such statement.


      CONTACT: Quick-Med Technologies, Inc.
      David S. Lerner, 561-750-4202
      dlerner@quickmedtech.com
      Investor Relations, 403-203-4748
      info@quickmedtech.com

      SOURCE: Quick-Med Technologies, Inc.
      Avatar
      schrieb am 23.01.05 18:46:26
      Beitrag Nr. 7 ()
      Hallo,

      ich habe gerade von diesem Wert gelesen und würde gerne Eure Meinung dazu hören.

      @MCG, mir scheint du findest immer wieder eine Perle, diese hast du ja auch entdeckt. ;) Hast du darüber genauere Informationen?

      Gruss Rosso


      Beitrag zu dieser Diskussion schreiben


      Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
      Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie
      hier
      eine neue Diskussion.
      +++ Und wieder 27 % Plus +++